logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Regeneron Granted FDA Emergency Use Authorization for its COVID-19 Antibody Cocktail Therapy

Regeneron Pharmaceuticals Receives EUA from the FDA for REGEN-COV2 Regeneron Pharmaceuticals’ ( REGN ) antibody cocktail therapy casirivimab and imdevimab, known also REGN-COV2 or REGEN-COV2 , received Emergency Use Authorization ( EUA ) from the U.S. Food and Drug Administration...

Read More

November 22, 2020

0

Let's Talk About 3 Firms with Important News: Cassava Sciences, Vertex Pharmaceuticals and Gilead Sciences

Cassava Sciences, Vertex Pharmaceuticals and Gilead Sciences All Have Good News Cassava Sciences & Alzheimer's Disease Cassava Sciences ( SAVA ) announced the initiation of a second Phase 3 trial of simufilam, its investigational drug for Alzheimer’s disease. This second...

Read More

November 19, 2021

0

The FDA Granted Orphan Drug Designation to Regenxbio Investigational Gene Therapy Drug RGX-202 for Duchenne Muscular Dystrophy

Regenxbio Granted Orphan Drug Designation for RGX-202 Regenxbio ( RGNX ) announced the U.S. FDA granted Orphan Drug Designation for RGX-202 - a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy. RGX-202 is designed to deliver a...

Read More

November 23, 2021

0

The Latest from Reata Pharmaceuticals. See Also: Prohost Picks that Reached the Moon in Today's Trading

Reata Pharmaceuticals We picked Reata Pharmaceuticals ( RETA ) for investment after confirming that the products the Company has created and is currently developing have a novel mechanism of action that enables the treatment of severe diseases that have yet...

Read More

November 27, 2020

0

The FDA Approved Rhythm Pharmaceuticals Product IMCIVREE™ for Genetic Obesity due to POMC, PCSK1 or LEPR Deficiency

Rhythm Pharmaceuticals FDA Approval of IMCIVREE™ for Genetic Obesity At the end of the trading week last Friday, November 27, 2020, the United States FDA approved Rhythm Pharmaceuticals’ ( RYTM ) product IMCIVREE™ (setmelanotide). The product is designed to treat...

Read More

December 1, 2020

0

Incyte Announces the FDA Approved its Opzelura Cream for the Treatment of Vitiligo

Incyte Announces FDA Approval of Opzelura Cream for Vitiligo Incyte ( INCY ) announced today, July 19, 2022, that the United States Food and Drug Administration ( FDA ) has approved Opzelura™ (ruxolitinib) cream 1.5% for the topical treatment of...

Read More

July 20, 2022

0

Why Intellia Therapeutics' and Moderna's Stocks Moved South Yesterday

Intellia Therapeutics Intellia Therapeutics ( NTLA ) stock price headed south probably because some robots learned that the firm commenced an underwritten public offering of $150 million of shares of its common stock. In addition to the commenced public offering Intellia announced...

Read More

December 2, 2020

0

Amgen: Positive Results from Otezla® Phase 3 DISCREET Study in Moderate to Severe Genital Psoriasis

Amgen Announces Positive Results from Otezla Study for Psoriasis Amgen ( AMGN ) announced positive top-line results from the DISCREET trial - a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla® (apremilast) in adults with moderate...

Read More

December 2, 2021

0

Seagen and Astellas Pharma Announced Positive Topline Results For PADCEV® with KEYTRUDA® as First-Line Treatment for Advanced Urothelial Cancer

Seagen, Astellas Pharma & Merck Collaboration Seagen ( SGEN ) and Astellas Pharma ( ALPMY ) have entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen’s and Astellas’ product PADCEV® (enfortumab vedotin-ejfv) with Merck’s ( MRK...

Read More

July 26, 2022

0

Bristol-Myers Squibb Combination Improving the Treatment of Metastatic Melanoma; AbbVie Improving the Treatment of Crohn's Disease

Offsetting the Biotech Firms' Good News There is no doubt that good news is filling the media about outperformances of both development-stage small biotech firms and revenues-generating firms. This good news has been offset by inflation, hiked interest rates, that...

Read More

July 29, 2022

0

  • Previous
  • 1
  • 2
  • ...
  • 34
  • 35
  • 36
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy